HGH Fragment 176-191: Risks & Legal Status

Critical Safety Information#

HGH Fragment 176-191 is a research compound that has not been approved for human use by any major regulatory agency. This page provides risk information for educational purposes only.

Growth Factor and Angiogenesis Risks#

HGH Fragment 176-191 (AOD9604) is a C‑terminal human growth hormone fragment developed for metabolic effects. Safety considerations span growth factor signaling, immune effects, and quality control of peptide preparations.

Growth factor/IGF-1 and mitogenicity

• IGF‑1 stimulation: Sponsor-associated preclinical and limited clinical summaries report that AOD9604 did not stimulate IGF‑1 production in examined systems, suggesting it does not activate the canonical GH→IGF‑1 axis that mediates many mitogenic effects. However, absence of IGF‑1 induction does not exclude other proliferative pathways and long‑term mitogenic risks remain insufficiently characterized.
• Genotoxicity: Standard assays (Ames, chromosome aberration, micronucleus) were largely negative, though isolated, non‑dose‑related or non‑reproducible positive signals occurred (e.g., slight increases in revertants in one strain; small rises in micronuclei at some doses). Overall conclusion in the nonclinical review was “no genotoxic concerns,” but sporadic findings warrant cautious interpretation.
• Systemic toxicology: Repeated‑dose studies identified NOAELs of ≥100 mg/kg/day in rats and ≥50 mg/kg/day in cynomolgus monkeys without consistent treatment‑related pathology, supporting a safety margin in animals; human translation is uncertain.

Immune modulation and immunogenicity

• Anti‑drug antibodies: Long‑term animal studies reported no significant anti‑AOD9604 antibodies by EIA at 13–39 weeks, suggesting low humoral immunogenicity in those models.
• Immune organ effects: Despite negative antibody tests, high‑dose male animals exhibited reduced thymus mass and decreased cortical width, indicating potential effects on lymphoid tissues at higher exposures.
• General peptide immunogenicity context: Peptides are typically less immunogenic than larger protein therapeutics, but immune responses can occur and depend on sequence, formulation, route, and impurities; illicit or modified preparations may alter this risk.

Peptide sourcing and quality control

• Identity and stability: Pharmacokinetic and radiolabel studies show rapid enzymatic degradation with sequential N‑terminal truncation, yielding circulating fragments with different kinetics and potentially different activity. This complicates analytical identification and stability claims and underscores the need for validated assays distinguishing intact peptide from degradants.
• Assay/solubility artifacts: In vitro work noted precipitation and unexpected toxicity at high concentrations, which can confound test results if not carefully controlled; such behavior also signals formulation challenges that QC should address.
• Gray‑market products: Doping-control literature highlights that custom‑synthesized peptides sold online often lack rigorous QC, with risks of incorrect sequence, variable purity/potency, and contaminants (e.g., endotoxin, residual solvents). These factors increase safety risk for end users of non‑regulated AOD9604 products.

Evidence limitations

• Much of the compound‑specific safety evidence is sponsor-associated and preclinical; independent human data on long‑term growth‑factor signaling, neoplasia risk, and immune modulation are limited. Conflict‑of‑interest considerations warrant caution in interpreting favorable safety conclusions.

Key points are summarized below.

Regulatory and Legal Status#

We reviewed peer‑reviewed anti‑doping literature addressing the regulatory posture of AOD‑9604 (HGH fragment 176–191) because direct regulator documents were not retrievable in our evidence set. Across sources, AOD‑9604 is consistently characterized as not approved for therapeutic use by governmental health authorities and treated under anti‑doping rules as a non‑approved substance.

Definition and naming AOD‑9604 is the C‑terminal fragment of human growth hormone (residues 176–191), a 16‑amino‑acid peptide investigated as an anti‑obesity candidate. It has been evaluated in small clinical studies and discussed in anti‑doping surveillance literature.

United States (FDA)

• Status: No FDA marketing authorization for therapeutic use was identified. One review notes a GRAS assessment for intended oral/food use, which is distinct from drug approval and does not confer prescription or over‑the‑counter medicine status. Anti‑doping literature describes AOD‑9604 as a “non‑approved peptidic compound.” No recent FDA changes were identified in the period surveyed by the anti‑doping reviews.

European Union (EMA)

• Status: No EMA‑authorized medicinal product containing AOD‑9604 was identified in the evidence reviewed; anti‑doping sources treat it as non‑approved for therapeutic use in the EU. No recent EU‑wide regulatory changes were noted in the surveyed period.

Australia (TGA)

• Status: No evidence in the retrieved literature of a TGA‑approved medicine containing AOD‑9604; anti‑doping sources treat it as non‑approved for therapeutic use. No recent TGA changes were identified in the surveyed period.

United Kingdom (MHRA)

• Status: No evidence in the retrieved literature of an MHRA‑licensed medicine containing AOD‑9604; anti‑doping sources treat it as non‑approved for therapeutic use. No recent MHRA changes were identified in the surveyed period.

Canada (Health Canada)

• Status: No evidence in the retrieved literature of a Health Canada‑authorized product containing AOD‑9604; anti‑doping sources treat it as non‑approved for therapeutic use. No recent Health Canada changes were identified in the surveyed period.

Anti‑doping classification

• Multiple anti‑doping reviews indicate AOD‑9604 is handled under WADA’s S0 category (Non‑Approved Substances), which encompasses substances without current approval for human therapeutic use by any governmental regulatory health authority. While the excerpted table associating S0 with AOD‑9604 was partial, the placement is consistent with broader anti‑doping literature stating a lack of governmental approval for such peptides.

Recent regulatory changes

• Within the time window covered by the retrieved anti‑doping reviews (through 2024 for the annual review), no new governmental therapeutic approvals or reclassifications for AOD‑9604 were identified (thevis2025annualbanned‐substancereview pages 4-4).

Limitations and practical implications

• Our evidence set did not include primary regulator webpages (FDA, EMA, TGA, MHRA, Health Canada) or formal scheduling/compounding policy documents. Nonetheless, peer‑reviewed anti‑doping sources converge that AOD‑9604 lacks therapeutic approval by governmental health authorities and is treated as a non‑approved substance in sport.

At-Risk Populations#

We assessed which populations are at highest risk when using HGH Fragment 176–191 (AOD9604), focusing on pregnancy, cancer, immunocompromise, and concurrent anticoagulant therapy. We synthesized preclinical toxicology and pharmacology, limited human safety summaries, mechanistic considerations (GH/IGF‑1 axis), and the absence of registered clinical trials.

Key evidence base Preclinical genotoxicity assays (Ames, CHO, micronucleus) were negative; chronic oral toxicology in rats (26 weeks) and cynomolgus monkeys (9 months) identified no treatment‑related toxicity and high NOAELs, and the peptide was non‑immunogenic in these species (no anti‑AOD9604 antibodies). Pharmacokinetics show rapid plasma clearance and oral degradation; AOD9604 did not stimulate IGF‑1 production and is not a high‑affinity GH‑receptor binder in studied systems. Human data are summarized across six early studies (including IV and oral, with two phase IIb trials) as “safe and well tolerated,” but details on special populations are not provided. A ClinicalTrials.gov search yielded no registered AOD9604 trials in the current dataset. Broader GH literature highlights diabetogenic and angiogenic effects for intact GH, underscoring theoretical risks in pregnancy and cancer when extrapolating mechanistically, though AOD9604 lacks IGF‑1 stimulation in tested systems.

Special populations at highest risk or warranting avoidance

• Pregnancy: No pregnancy‑specific human or animal reproductive data for AOD9604 were identified in the gathered record; no registered pregnancy trials were found. Given the role of the GH/IGF axis in fetal/placental biology and the diabetogenic/angiogenic concerns noted for intact GH, pregnancy should be considered a high‑risk group; avoid use pending pregnancy‑specific safety data.
• Active or recent cancer: No trials in cancer populations were identified. Although AOD9604 did not increase IGF‑1 in studied systems and is not a high‑affinity GH‑receptor binder, the GH/IGF‑1 axis can support proliferation and angiogenesis in malignancy. Without cancer‑specific safety or long‑term oncogenicity data, patients with active or recently treated cancer should be considered high risk; avoid use or restrict to research settings with oncology oversight.
• Immunocompromised individuals: Animal studies reported no immunogenicity (no anti‑AOD9604 antibodies), but human immunologic data are sparse and not stratified by immune status. Infection risk or vaccine response effects were not evaluated. Given evidence gaps, use caution or avoid outside controlled studies in markedly immunocompromised patients.
• Those on anticoagulants: No AOD9604‑specific data on coagulation parameters, platelet function, or bleeding were found. No mechanistic signal for coagulation effects emerged from the gathered sources, but absence of evidence is not evidence of safety. Recommend caution and clinical monitoring if co‑administered; avoid unsupervised use.

Practice implications

• AOD9604 appears non‑genotoxic and well tolerated in short‑term human studies and chronic animal toxicology, and it does not stimulate IGF‑1 in tested systems; however, direct evidence in the queried high‑risk populations is absent. Therefore, pregnancy and active/recent cancer should be regarded as highest‑risk groups requiring avoidance. Immunocompromise and concurrent anticoagulation warrant caution due to lack of data and should be limited to medically supervised contexts.

Embedded evidence summary

Risk Mitigation#

For Researchers#

1. Use only from verified, third-party tested sources
2. Follow proper handling and sterility protocols
3. Document all observations carefully
4. Report adverse events

General Precautions#

1. Consult healthcare providers before any use
2. Start with lowest suggested amounts in research protocols
3. Monitor for any adverse effects
4. Discontinue immediately if problems arise

Related Reading#

• HGH Fragment 176-191 overview and research guide
• HGH Fragment 176-191 side effects profile
• HGH Fragment 176-191 research evidence